Diligence memo · auto-generated · as of July 2, 2026
Instylla, Inc.
Instylla, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Instylla, Inc. operates in Biotechnology, based in BEDFORD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Instylla, Inc. has raised $86M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2023-08-08.
Most recent recorded round closed around 2025-07-07.
Valuation (modeled)modeled
Provath models Instylla, Inc. at approximately $100M (range $43M–$148M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.29× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 12 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 89% of Biotechnology peers (4293 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.